BrightSpring Health Services has been named a Zacks Rank 1 Strong Buy, driven by strong momentum in its Specialty and Infusion segment and the integration of acquired home health assets. In the first quarter of 2026, Specialty and Infusion revenues surged 36% year over year to $2.64 billion, while Provider Services revenues rose 28% to $442 million, including a 49% jump in Home Health Care revenues to $266 million. The company raised its full-year adjusted EBITDA outlook, though it faces headwinds from the Inflation Reduction Act and brand-to-generic conversions expected to reduce 2026 revenues by roughly $600 million. BrightSpring shares have rallied 84.2% year to date, far outpacing the industry's 2.3% decline and the S&P 500's 8.9% gain.
BrightSpring Health Services, Inc. Common StockZacks Rank 1 Strong Buy rating and raised adjusted EBITDA outlook
Globus Medical
Hinge Health, Inc.
West Pharmaceutical Services Inc